No Picture
Los Angeles Biotech Trending News

German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia®, Inc. announced today that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group (AGO) guidelines. The assay was added to […]

Los Angeles Biotech Trending News

TORL Targets Hot ADC Space with Oversubscribed $158M Series B-2

Published: Apr 10, 2024 By Tristan Manalac Pictured: Antibody-drug conjugate with cytotoxic payload/iStock, Love Employee Los Angeles-based startup TORL BioTherapeutics on Wednesday closed a $158 million oversubscribed Series B-2 funding round, which will… Click here to […]

Los Angeles Biotech Trending News

Hoag Announces $25 Million Gift to Boldly Hoag Campaign

Du Family Hospital Pavilion Named in Support of Hoag’s Bold Expansion in Irvine IRVINE, Calif., April 8, 2024 /PRNewswire/ — Scheduled to open in 2026, Hoag’s reimagined Sun Family Campus in Irvine will be built […]

Los Angeles Biotech Trending News

Merck buys Abceutics to make ADCs safer

Antibody-drug conjugates have caught the biopharma world by storm, and Merck has been an active dealmaker in the space via multibillion-dollar pacts with Daiichi Sankyo and Sichuan Kelun-Biotech. Now, the New Jersey pharma giant is […]

No Picture
Los Angeles Biotech Trending News

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG). Results […]

No Picture
Los Angeles Biotech Trending News

New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease

IRVINE, Calif.–(BUSINESS WIRE)–Cloudbreak Pharma, a clinical stage biotechnology company developing ophthalmic drugs for common eye diseases with few treatment options, shared new data from a company-supported survey highlighting the patient burden of pterygium at the […]